Free tool
Drug Trial Radar: Pain and anesthesia
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
25
Recruiting, industry sponsors, Pain and anesthesia, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed433
25 trials
Showing 1 to 25, recently updated first.
Consano BioIndustry
NCT07264270 · 24 participants (planned) · Start Dec 3, 2025 · Primary completion Jun 2027
Drug: C-1101 · For: Lumbosacral Radicular Pain; Sciatic Radiculopathy; Sciatic Leg Pain and 3 more
Sites: Fernandina Beach, Florida; Winston-Salem, North Carolina; Richmond, Virginia · 6 sites in all
Iongen Therapeutics Co., Ltd.Industry
NCT07618247 · 96 participants (planned) · Start Jul 7, 2026 · Primary completion Apr 30, 2027
Drug: Placebo; IG001119 · For: Pain
Sites: Adelaide, Australia; Christchurch, New Zealand
Cytogel Pharma, LLCIndustry
NCT07905105 · 32 participants (planned) · Start Sep 25, 2026 · Primary completion Oct 2027
Drug: CYT-1010; Placebo · For: Acute Postoperative Pain; Dental Pain
Sites: Salt Lake City, Utah
- Evaluation of Intra-articular CX-011 to Treat Moderate to Severe Pain From Knee OsteoarthritisRecruiting
CarthroniX, Inc.Industry
NCT07308834 · 72 participants (planned) · Start Aug 11, 2026 · Primary completion Oct 30, 2028
Drug: CX-011 · For: Osteoarthritis of the Knees
Sites: Los Angeles, California
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT07519109 · 60 participants (planned) · Start Mar 30, 2026 · Primary completion Dec 31, 2026
Drug: SYH9089 injection; Ropivacaine hydrochloride and 1 more · For: Postoperative Pain
Sites: Changsha, China
- Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord InjuryRecruiting
EicOsis Human Health Inc.Industry
NCT06438471 · 36 participants (planned) · Start May 1, 2026 · Primary completion Dec 2027
Drug: EC5026 oral tablet; Placebo oral tablet · For: Spinal Cord Injuries; Neuropathic Pain; Degenerative Disc Disease and 2 more
Sites: Augusta, Georgia
HALEONIndustry
NCT07632274 · 12 participants (planned) · Start Jun 19, 2026 · Primary completion Sep 2026
Drug: Test Product · For: Pain
Sites: Salt Lake City, Utah
Alcamena Stem Cell TherapeuticsIndustry
NCT07363395 · 72 participants (planned) · Start Jan 6, 2026 · Primary completion Oct 1, 2026
Drug: ASCT-83; Placebo · For: Neuropathic Pain
Sites: Saint Paul, Minnesota
Telix Pharmaceuticals (Innovations) Pty LimitedIndustry
NCT07197645 · 33 participants (planned) · Start Oct 21, 2025 · Primary completion Apr 26, 2027
Drug: 153Sm-DOTMP · For: Bone Pain; Metastatic Bone Tumor; Bone Metastases in Subjects With Advanced Cancer
Sites: Miami, Florida; Houston, Texas · 6 sites in all
- The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumbar Discogenic PainPivotal-lookingRecruiting
Sclnow Biotechnology Co., Ltd.Industry
NCT04104412 · 242 participants (planned) · Start Aug 15, 2019 · Primary completion Dec 31, 2026
Drug: human umbilical cord mesenchymal stem cell · For: Lumbar Discogenic Pain
Sites: Beijing, China
- A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic PainPivotal-lookingRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07377721 · 168 participants (planned) · Start Mar 24, 2026 · Primary completion Sep 2026
Drug: HRS-2129 Tablets; HRS-2129 Placebo and 2 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Beijing, China; Chongqing, China
Centrexion TherapeuticsIndustry
NCT07122453 · 16 participants (planned) · Start Mar 2026 · Primary completion Jan 2027
Drug: CNTX-3001; Placebo · For: Lower Back Pain
Sites: Napa, California
Tafalgie TherapeuticsIndustry
NCT06789861 · 94 participants (planned) · Start May 23, 2025 · Primary completion Oct 1, 2026
Drug: TT5; Placebo - TT5 vehicle · For: Pain
Sites: Adelaide, Australia
Sparian Biosciences, IncIndustry
NCT07335913 · 80 participants (planned) · Start Jan 8, 2026 · Primary completion Jan 31, 2027
Drug: SBS-147; Placebo · For: Pain Acute; Pain
Sites: Cypress, California
Grünenthal GmbHIndustry
NCT07289776 · 70 participants (planned) · Start Jan 14, 2026 · Primary completion Aug 24, 2026
Drug: GRT7041 SAD; Placebo and 2 more · For: Treatment of Pain
Sites: Christchurch, New Zealand
Pacira Pharmaceuticals, IncIndustry
NCT06271265 · 48 participants (planned) · Start Mar 29, 2024 · Primary completion Jan 2027
Drug: EXPAREL; bupivacaine · For: Postoperative Pain
Sites: Indianapolis, Indiana; St Louis, Missouri; Durham, North Carolina · 5 sites in all
Tr1X, Inc.Industry
NCT06721962 · 39 participants (planned) · Start May 5, 2025 · Primary completion Jan 30, 2026
Drug: TRX103; Cyclophosphamide · For: Crohns Disease
Sites: Scottsdale, Arizona; Sacramento, California; San Francisco, California · 13 sites in all
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.Industry
NCT06361108 · 24 participants (planned) · Start May 16, 2024 · Primary completion Dec 20, 2025
Drug: YJ001 for Spray Use; Placebo of YJ001 for Spray Use · For: Diabetic Peripheral Neuropathic Pain
Sites: Fredericksburg, Texas
4B Technologies LimitedIndustry
NCT06343714 · 64 participants (planned) · Start Apr 7, 2024 · Primary completion Feb 28, 2026
Drug: FB1003; Placebo · For: Healthy Volunteers
Sites: Brisbane, Australia; Bayswater, Australia
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT07008703 · 132 participants (planned) · Start Mar 27, 2024 · Primary completion Dec 2025
Drug: Injection of humanized nerve growth factor (NGF) antibody · For: Cancer Pain
Sites: Zhengzhou, China
Arcato Laboratories, Inc.Industry
NCT06864884 · 30 participants (planned) · Start Feb 26, 2025 · Primary completion Feb 2026
Drug: ARC-001; Placebo gel · For: Acute Post Operative Pain; Third Molar Extraction Surgery
Sites: Salt Lake City, Utah
- Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone FractureRecruiting
ZetrOZ, Inc.Industry
NCT05883241 · 90 participants (planned) · Start Jun 1, 2023 · Primary completion Feb 1, 2026
Drug: 2.5% Diclofenac Patches · For: Bone Fracture; Fresh Fracture
Sites: Trumbull, Connecticut; Lansdowne, Virginia
ZetrOZ, Inc.Industry
NCT05254574 · 200 participants (planned) · Start Feb 14, 2022 · Primary completion May 1, 2026
Drug: 2.5% Diclofenac Patches · For: Osteoarthritis
Sites: Tampa, Florida
- Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee OsteoarthritisPivotal-lookingRecruiting
R3 Medical ResearchIndustry
NCT06608134 · 120 participants (planned) · Start Oct 1, 2024 · Primary completion Oct 1, 2028
Drug: Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection · For: Osteoarthritis, Knee
Sites: Scottsdale, Arizona; Beverly Hills, California; Fresno, California · 5 sites in all
- Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar PainRecruiting
R3 Stem CellIndustry
NCT06361485 · 100 participants (planned) · Start Mar 25, 2024 · Primary completion Mar 31, 2027
Drug: Lumbar Injections with 10cc's of Wharton's Jelly Allograft · For: Low Back Pain
Sites: Scottsdale, Arizona; Beverly Hills, California; New York, New York · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.